Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.
Biolytx Pharmaceuticals develops a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
Jortan Pharmaceuticals Inc.?(JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF).
GG Companies develops a powerful arthritis rub, a topical herbal gel used to soothe painful areas.
Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.
Otologic Pharmaceutics, Inc. is an organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balance health.
Respiron is developing an antiviral drug, RN-1, to treat any existing and emerging strains of influenza virus. It can potentially cure flu symptoms in nearly 300 million people worldwide regardless of virus mutation.
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
UltraBotanica has developed a patented method to bind curcumin to whey protein, effectively increasing the bioavailability by 15,000x.
PreDENT has developed a vaccine to help prevent gingivitis and periodontal disease in pets?that produces significant pain and possibly even fatal damage to an animal?s organs.
Plymouth Pharmaceuticals, Inc. is a leading research and development company exploring safe, effective, oral therapies for inflammatory skin disorders.?Plymouth offers Rx and OTC products for psoriasis, eczema, acne and seborrhea dermatitis.
DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.
Advance Research Chemicals, Inc. offers basic and advanced chemical applications and services in a wide array of industries including military defense,?semiconductors, battery materials, pharmaceuticals, medical devices, automotive components, textiles, agricultural solutions, surfactants and industrial cleaners.
COARE Biotechnology is a research driven pharmaceutical company dedicated to developing novel therapeutic agents designed to treat solid tumor cancers.
Sensuli, LLC is developing a true once-a-day glucose-responsive insulin that may mimic a healthy human pancreas. Sensulin? may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.
Pamlico Biopharma has developed personalized, targeted human antibody therapeutics against severe pneumonia that were created using patent-pending methodology from the Oklahoma Medical Research Foundation.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
Selexys is a development stage biopharmaceutical company focused on the treatment of inflammatory and thrombotic diseases. ?The company has developed antibodies that block recruitment of white blood cells to activated endothelium and platelets. ?
Charlesson is an ocular pharmaceutical company that is developing therapeutics for various eye diseases, including wet and dry Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Uveitis.
Anastasia Marie Labs, Inc. specializes in over-the-counter diabetic skin treatment products.
A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed? Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Mills’ state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems.